You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《半新股》開拓藥業-B(09939.HK)由紀錄低急彈21%高見17.48元 聘ABI研治新冠肺炎藥物
阿思達克 07-13 10:43
開拓藥業-B(09939.HK)扭四連跌,股價由上市低位急彈重越10天及20天線(15.25-15.32元),最高見17.48元,現造17.34元,急彈21%,成交急增至598萬股,創逾一個月高,涉資9,736萬元。

開拓藥業是一間仍未有盈利生物公司。股份於5月22日以每股20.15元上市,首掛日高見22.95元已行人止步,上市翌日收市價開始「潛水」至今。

開拓藥業公布,全資子公司蘇州開拓藥已訂立臨床試驗研協議,聘請美國生物公司Applied Biology Inc.(ABI)進行集團在研藥物普克魯胺(GT0918)治療新冠肺炎(COVID-19)研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account